CTOs on the Move

Omega Therapeutics

www.omegatherapeutics.com

 
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

PT Development LLC.

PT Development (PTD) is a Louisville-based operational management firm that specializes in providing operational efficiencies such as accounting, customer service, marketing, compliance, and human resource services to privately held physical therapy practices.   Founded by Dr. Larry Benz in 1994, PTD’s primary goal is to help our clients achieve clinical excellence through aligning business strategies, streamlining processes, and building equity through quality customer service.

Vysis

Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affitech USA

Affitech USA is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Just. Biotherapeutics

Just. is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. We believe that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.

Viracta

Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.